A high-throughput functional assay for characterization of gamma-aminobutyric acid(A) channel modulators using cryopreserved transiently transfected cells.
The ionotropic -aminobutyric acid (GABA)A receptors are an important family of drug targets for a variety of neurological and psychiatric disorders. Selective modulation of certain subtypes of the receptor could lead to novel or improved therapies. However, the discovery of subtype-selective compounds has been hampered by the lack of a high-throughput functional assay and the difficulty in establishing stable cell lines expressing GABAA receptor in a proper subunit composition. To meet drug discovery need we developed a fluorescent imaging plate reader(FLIPR)-based membrane potential assay with sufficient robustness and reproducibility for use in a high-throughput format. Two major subtypes of GABAA receptor were used: GABAA1 and GABAA2, which are composed of (alpha1)2(beta2)2gama2 and (alpha1)2(beta3)2gama2, respectively. We expressed the receptors by transiently co-transfecting cells with the three subunit DNAs in separate constructs, and by controlling the ratio of the DNA amount for each subunit transfected we forced the cells to express GABAA receptors in a pharmacologically relevant form. A large batch of transfected human embryonic kidney 293 cells were cryopreserved and used to screen and evaluate GABAA modulators.In these cells, agonist activation of GABAA receptor resulted in Cl- efflux and membrane depolarization, which was detected by FLIPR as an increase in fluorescence signal. Based on our characterization of several known GABAA modulators and a test set of compounds known to bind to the GABAA benzodiazepine site, we have demonstrated the validity and utility of this assay for discovery of novel pharmacological agents acting at GABAA receptors.
Liu
Jay
J
HTS Center and Global Support Department, AstraZeneca Pharmaceuticals, C253H Wilmington, DE 19850, USA. jay.liu@astrazeneca.com
Chen
Tongming
T
Norris
Tyrell
T
Knappenberger
Kathy
K
Huston
Julie
J
Wood
Michael
M
Bostwick
Robert
R
D002243:Carbolines / Q000494:pharmacology; D018929:Cell Culture Techniques; D002460:Cell Line; D002462:Cell Membrane; D015925:Cryopreservation; D004247:DNA / Q000235:genetics; D003975:Diazepam / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D055808:Drug Discovery / Q000379:methods*; D005442:Flumazenil / Q000494:pharmacology; D005445:Flunitrazepam / Q000494:pharmacology; D005456:Fluorescent Dyes / Q000378:metabolism; D005464:Fluorobenzenes / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists; D006801:Humans; D008564:Membrane Potentials; D011963:Receptors, GABA-A / Q000737:chemistry / Q000235:genetics; D015203:Reproducibility of Results; D013050:Spectrometry, Fluorescence; D014162:Transfection; D014230:Triazoles / Q000494:pharmacology; D014316:Tritium / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000235:genetics
D002243:Carbolines; D005456:Fluorescent Dyes; D005464:Fluorobenzenes; D058787:GABA-A Receptor Antagonists; D011963:Receptors, GABA-A; D014230:Triazoles; D014316:Tritium; C034818:methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate; D005442:Flumazenil; D005680:gamma-Aminobutyric Acid; D005445:Flunitrazepam; C049504:N-butyl beta-carboline-3-carboxylate; C409903:L 838,417; D004247:DNA; D003975:Diazepam